Neurocrine Bio. (NBIX) PT Lowered to $187 at RBC Capital

September 21, 2026 8:24 AM

RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $187.00 (from $198.00) while maintaining a Outperform rating.

No results found